^
    Back
    Association details:
    Biomarker:PDGFRA exon 18 mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/30/2020
    Excerpt:
    For PDGFRA exon 18 mutations, consider dasatinib (for PDGFRA D842V mutation) or imatinib (for imatinib-sensitive PDGFRA exon 18 mutations).